Setara Biosciences Announces $90 Million Series A Financing
Setara Biosciences announced a $90 million Series A financing to advance precision medicines for rare genetic diseases and related expansion indications. The company was created following Jazz Pharmaceuticals’ acquisition of Actio Biosciences.